¼¼°èÀÇ Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀå
Insulin Injection Aids
»óǰÄÚµå : 1783989
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 280 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3¾ï 3,790¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 4,370¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 3,790¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Àν¶¸° ¹ÙÀÌ¾Ë º¸Á¶±â±¸´Â CAGR 4.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 1,260¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ã¸°Áö º¸Á¶±â±¸ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6,640¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀåÀº 2024³â¿¡ 6,640¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 8.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 6,700¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.8%¿Í 5.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ¼ö¿ä È®´ëÀÇ ¿øµ¿·ÂÀº?

Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ¼¼°è ½ÃÀåÀº Àü ¼¼°è ´ç´¢º´ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î Å« ÆøÀÇ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸Í(IDF)¿¡ µû¸£¸é, 2045³â±îÁö ´ç´¢º´ ȯÀÚ ¼ö°¡ 7¾ï ¸íÀ» ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ¾î È¿°úÀûÀÎ Àν¶¸° Åõ¿© ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Àν¶¸° ÁÖ»ç Ææ, ´Ïµé °¡À̵å, Àν¶¸° ÁÖÀÔ±â, ¾ÈÀü ÁÖ»ç±â µî Àν¶¸° ÁÖÀÔ º¸Á¶±â±¸´Â ȯÀÚÀÇ Àν¶¸° Åõ¿©ÀÇ Á¤È®¼º, ¾ÈÀü¼º, ÆíÀǼºÀ» ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº ȯÀÚ Ä£È­ÀûÀÎ ÃÖ¼Òħ½ÀÀû Àν¶¸° Åõ¿© ¹æ½ÄÀ¸·ÎÀÇ ÀüȯÀÔ´Ï´Ù. ƯÈ÷ ´ç´¢º´ Áø´ÜÀ» ¹ÞÀº Áö ¾ó¸¶ µÇÁö ¾ÊÀº ȯÀÚµéÀº ÁÖ»ç¹Ù´Ã¿¡ ´ëÇÑ ºÒ¾È°¨À̳ª ºÎÀûÀýÇÑ ½Ã¼ú·Î ÀÎÇØ ÀÚ°¡Áֻ翡 ¾î·Á¿òÀ» °Þ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Àν¶¸° ÁÖ»ç º¸Á¶±â±¸´Â Áֻ縦 º¸´Ù Æí¾ÈÇÏ°Ô Çϰí Åõ¾à ½Ç¼öÀÇ À§ÇèÀ» ÁÙ¿© Ä¡·á ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç´¢º´ Ä¡·áÀÇ ÀÚ°¡ °ü¸®ÀÇ È®»ê°ú ÇÔ²² ƯÈ÷ ³ëÀÎ ¹× ¼Ò¾Æ ȯÀÚµé »çÀÌ¿¡¼­ »ç¿ëÇϱ⠽¬¿î Àν¶¸° Åõ¿© º¸Á¶±â±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº Àν¶¸° ÁÖ»ç º¸Á¶±â±¸¸¦ ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

±â¼ú Çõ½ÅÀº Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀåÀ» º¯È­½Ã۰í ÀÖÀ¸¸ç, ´ç´¢º´ °ü¸®¸¦ º¸´Ù È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ¹ßÀü Áß Çϳª´Â Àν¶¸° ¿ë·®, ÁÖ»ç ½Ã±â, ¼øÀÀµµ¸¦ ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ½º¸¶Æ® Àν¶¸° Ææ°ú Ä¿³ØÆ¼µå ÁÖ»ç º¸Á¶±â±¸ÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ ½º¸¶Æ® ±â±â´Â ¸ð¹ÙÀÏ °Ç°­ ¾ÖÇø®ÄÉÀ̼ǰú µ¿±âÈ­µÇ¾î ȯÀÚ¿Í ÀÇ·áÁøÀÌ Àν¶¸° »ç¿ë·®À» ÃßÀûÇϰí, Åõ¿© ´©¶ôÀ» °¨ÁöÇϰí, Ä¡·á °èȹÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÁÖ¿ä ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº Àν¶¸° Àü´Þ º¸Á¶ ÀåÄ¡¿¡ ºí·çÅõ½º ¹× IoT(»ç¹°ÀÎÅͳÝ) ±â´ÉÀ» ÅëÇÕÇÏ¿© µ¥ÀÌÅÍ ±â¹Ý ´ç´¢º´ °ü¸®¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« Çõ½ÅÀº Á¦Æ® ÀÎÁ§ÅÍ¿Í °°Àº ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ÁÖ»ç ±â¼úÀÇ µµÀÔÀÔ´Ï´Ù. Á¦Æ® ÀÎÁ§ÅÍ´Â °í¾Ð °ø±â¸¦ ÀÌ¿ëÇØ ¹Ù´Ã ¾øÀÌ Àν¶¸°À» ÁÖÀÔÇÏ´Â ¹æ½ÄÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÁÖ»ç¹Ù´Ã °øÆ÷Áõ ÇØ¼Ò, ÁÖ»çºÎÀ§ ºÒÆí°¨ °¨¼Ò, ȯÀÚ ¼øÀÀµµ Çâ»ó¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿ ÁÖ»ç±â³ª °¡À̵å ÁÖ»ç±â´Â ÃÖ¼ÒÇÑÀÇ ¼öÀÛ¾÷À¸·Î ÀϰüµÇ°í ÅëÁõ ¾øÀÌ Àν¶¸°À» Åõ¿©ÇÒ ¼ö ÀÖ¾î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¸Á¶±â±¸´Â ´ëºÎºÐ ÀÎü°øÇÐÀû µðÀÚÀÎÀÌ Æ¯Â¡À̸ç, ƯÈ÷ ³ëÀÎÀ̳ª °üÀý¿° ȯÀÚ µî ¼ÕÀÌ ºÒÆíÇÑ »ç¶÷µé¿¡°Ô À¯¿ëÇÕ´Ï´Ù.

Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ÀÇ »ç¿ëÀ» È®´ëÇÏ´Â »õ·Î¿î ÀÀ¿ë ºÐ¾ß´Â ¹«¾ùÀΰ¡?

ÀüÅëÀûÀÎ ´ç´¢º´ °ü¸®»Ó¸¸ ¾Æ´Ï¶ó Àν¶¸° ÁÖ»ç º¸Á¶±â±¸´Â »õ·Î¿î Ä¡·á ºÐ¾ß¿Í ÇコÄɾî ȯ°æÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Æ®·»µå Áß Çϳª´Â Á¤È®ÇÑ Åõ¾à°ú ¾ÈÀü¼ºÀÌ Áß¿äÇÑ º´¿ø¿¡¼­ Àν¶¸° Àü´Þ º¸Á¶±â±¸ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø ¾÷ü´Â »çÀü ÃæÀü µÈ Àν¶¸° Ææ°ú ¹Ù´Ã ¾ÈÀü ÀåÄ¡¸¦ äÅÃÇÏ¿© Åõ¾à ½Ç¼ö¸¦ ÁÙÀ̰í ÀÇ·áÁøÀÇ ¿ì¹ßÀû ÀÎ ¹Ù´Ã Âñ¸² »ç°í¸¦ ¿¹¹æÇÕ´Ï´Ù. ÀÏȸ¿ë Àν¶¸° ÁÖ»ç º¸Á¶±â±¸¿¡ ´ëÇÑ ¼ö¿ä´Â º´¿ø, ƯÈ÷ ¾ö°ÝÇÑ À§»ý ÇÁ·ÎÅäÄÝÀÌ ¿ä±¸µÇ´Â °¨¿° º´µ¿¿¡¼­µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Àν¶¸° ÁÖ»ç º¸Á¶ ÀåÄ¡¿Í Àΰø ÃéÀå ½Ã½ºÅÛ ¹× ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ÀåÄ¡¿ÍÀÇ ÅëÇÕÀ¸·Î ¿ëµµ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´ Ä¡·á°¡ ÀÚµ¿ Àν¶¸° Åõ¿©(AID) ¼Ö·ç¼ÇÀ¸·Î ÀüȯµÊ¿¡ µû¶ó ½Ç½Ã°£ Æ÷µµ´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀ» º¸¿ÏÇÏ´Â °í±Þ ÁÖ»ç º¸Á¶ ±â±â°¡ ¼³°èµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Ç÷´ç Á¶ÀýÀ» °³¼±Çϰí ÀÏ»óÀûÀÎ ´ç´¢º´ °ü¸®ÀÇ ºÎ´ãÀ» ´ú¾îÁÖ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý µ¥ÀÌÅÍ ºÐ¼®¿¡ ±â¹ÝÇÑ °³ÀÎÈ­µÈ Àν¶¸° Åõ¿© ¾Ë°í¸®ÁòÀ» »ç¿ëÇÏ¿© Àν¶¸° Åõ¿©ÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, ȯÀÚ °³°³ÀÎÀÇ Çʿ信 ¸Â´Â Ä¡·á¸¦ ½ÇÇöÇϰí ÀÖ½À´Ï´Ù.

Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´ À¯º´·ü Áõ°¡, ÀÚ°¡ °ü¸® ´ç´¢º´ °ü¸® ¼Ö·ç¼Ç äÅ÷ü Áõ°¡, Àν¶¸° Àü´Þ ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ³ëÀεéÀº Á¦2Çü ´ç´¢º´ÀÇ À§ÇèÀÌ ³ô±â ¶§¹®¿¡ Á¢±Ù¼ºÀÌ ÁÁ°í »ç¿ëÇϱ⠽¬¿î Àν¶¸° ÁÖ»ç º¸Á¶±â±¸°¡ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ¼Ò¾Æ ´ç´¢º´ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ÀÚµ¿ ÁÖ»ç±â ¹× ÅëÁõ ¿ÏÈ­ ÀåÄ¡¿Í °°Àº ¾î¸°ÀÌ Ä£È­ÀûÀÎ Àν¶¸° Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³Ã´À» ÃËÁøÇÏ´Â ¶Ç ´Ù¸¥ Å« ¿äÀÎÀº ½ÅÈï±¹¿¡¼­ÀÇ Àν¶¸° Àü´Þ ÀåÄ¡ÀÇ º¸±Þ È®´ëÀÔ´Ï´Ù. °¢±¹ Á¤ºÎ¿Í ÀÇ·á ±â°üÀº ´ç´¢º´ Ä¡·á Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇØ Àú·ÅÇÑ °¡°ÝÀÇ Çõ½ÅÀûÀÎ Àν¶¸° ÁÖ»ç º¸Á¶±â±¸¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÇ È®´ëµµ ½ÃÀå È®´ë¿¡ ÀÏÁ¶Çϰí ÀÖÀ¸¸ç, ȯÀÚµéÀº °¡»ó ´ç´¢º´ °ü¸® Ç÷§ÆûÀ» ÅëÇØ Àν¶¸° Åõ¿©¿¡ ´ëÇÑ ½Ç½Ã°£ ¾È³»¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú »óȯ Á¤Ã¥Àº ÷´Ü Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ½º¸¶Æ® Àν¶¸° Ææ, ÀÚµ¿ ÁÖ»ç±â, ¾ÈÀü ÁÖ»ç±â¸¦ ´ë»óÀ¸·Î Çϰí ÀÖ¾î ȯÀڵ鿡°Ô ´õ¿í Ä£¼÷ÇÏ°Ô ´Ù°¡¼­°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áö¼Ó°¡´É¼º°ú ģȯ°æ µðÀÚÀÎ Æ®·»µå°¡ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, Á¦Á¶¾÷üµéÀº ÀÇ·á Æó±â¹°À» ÁÙÀ̱â À§ÇØ »ýºÐÇØ¼º Àν¶¸° Ææ ºÎǰ°ú ÀçȰ¿ë °¡´ÉÇÑ ÁÖ»ç º¸Á¶±â±¸¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù.

´õ ¾ÈÀüÇϰí, ´õ ½º¸¶Æ®Çϰí, ´õ Æí¸®ÇÑ Àν¶¸° Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Àν¶¸° ÁÖ»ç º¸Á¶±â±¸ ½ÃÀåÀº ½º¸¶Æ® ±â¼ú, ¸ÂÃãÇü Åõ¾à, ¹Ù´Ã ¾ø´Â Àν¶¸° Àü´ÞÀÇ Çõ½ÅÀÌ ´ç´¢º´ Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÔ¿¡ µû¶ó È®´ëµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç°(Àν¶¸° ¹ÙÀÌ¾Ë º¸Á¶±â±¸, ½Ã¸°Áö º¸Á¶±â±¸, ÀÎÁ§ÅÍ, ¾Æµ¿¿ë º¸Á¶±â±¸, ±âŸ), ÃÖÁ¾»ç¿ë(º´¿ø, Àü¹® Ŭ¸®´Ð, ÀçÅÃÀÇ·á ÇöÀå, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Insulin Injection Aids Market to Reach US$337.9 Million by 2030

The global market for Insulin Injection Aids estimated at US$243.7 Million in the year 2024, is expected to reach US$337.9 Million by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Insulin Vial Aids, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$112.6 Million by the end of the analysis period. Growth in the Syringe Aids segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$66.4 Million While China is Forecast to Grow at 8.6% CAGR

The Insulin Injection Aids market in the U.S. is estimated at US$66.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$67.0 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Insulin Injection Aids Market - Key Trends & Drivers Summarized

What Is Driving the Growing Demand for Insulin Injection Aids?

The global insulin injection aids market is experiencing significant growth, driven by the rising prevalence of diabetes worldwide. According to the International Diabetes Federation (IDF), the number of people living with diabetes is projected to surpass 700 million by 2045, highlighting the increasing need for effective insulin administration solutions. Insulin injection aids, including injection pens, needle guides, insulin dosers, and safety syringes, play a crucial role in enhancing the accuracy, safety, and convenience of insulin delivery for patients.

Another key factor fueling market expansion is the shift towards patient-friendly and minimally invasive insulin administration methods. Many individuals, especially those newly diagnosed with diabetes, struggle with self-injection due to needle anxiety or improper technique. Insulin injection aids help improve adherence to treatment by making injections more comfortable and reducing the risk of dosing errors. With the increasing adoption of self-management practices in diabetes care, demand for user-friendly insulin delivery aids is on the rise, particularly among elderly and pediatric patients.

How Are Technological Advancements Enhancing Insulin Injection Aids?

Technological innovations are transforming the insulin injection aids market, making diabetes management more efficient and patient-friendly. One of the most notable advancements is the development of smart insulin pens and connected injection aids, which enable real-time monitoring of insulin dosage, injection timing, and adherence. These smart devices sync with mobile health applications, allowing patients and healthcare providers to track insulin usage, detect missed doses, and optimize treatment plans. Leading medical device manufacturers are incorporating Bluetooth and IoT (Internet of Things) capabilities into insulin delivery aids, improving data-driven diabetes management.

Another major innovation is the introduction of needle-free injection technologies, such as jet injectors, which use high-pressure air to deliver insulin without the need for a needle. These systems help eliminate needle phobia, reduce injection site discomfort, and improve patient compliance. Additionally, auto-injectors and guided injection devices are gaining popularity, as they provide consistent and painless insulin delivery with minimal manual effort. Many of these aids feature ergonomic designs, making them particularly useful for individuals with limited dexterity, such as elderly patients or those with arthritis.

What Are the Emerging Applications Expanding the Use of Insulin Injection Aids?

Beyond traditional diabetes management, insulin injection aids are expanding into new therapeutic areas and healthcare settings. One emerging trend is the increasing use of insulin delivery aids in hospital settings, where precision dosing and safety are critical. Healthcare providers are adopting pre-filled insulin pens and needle safety devices to reduce dosing errors and prevent accidental needlestick injuries among medical staff. The demand for disposable insulin injection aids is also growing in hospitals, particularly in infectious disease wards where strict hygiene protocols are required.

Another expanding application is the integration of insulin injection aids with artificial pancreas systems and continuous glucose monitoring (CGM) devices. As diabetes care moves toward automated insulin delivery (AID) solutions, advanced injection aids are being designed to complement real-time glucose monitoring systems. These innovations help improve glycemic control and reduce the burden of daily diabetes management. Additionally, the use of personalized insulin dosing algorithms, based on AI-driven data analytics, is enhancing the precision of insulin administration, making treatment more tailored to individual patient needs.

What Are the Key Growth Drivers Shaping the Future of the Insulin Injection Aids Market?

The growth in the insulin injection aids market is driven by several factors, including increasing diabetes prevalence, rising adoption of self-care diabetes management solutions, and continuous advancements in insulin delivery technology. One of the primary growth drivers is the aging global population, as older adults are at higher risk for type 2 diabetes and require accessible and easy-to-use insulin injection aids. Additionally, the rising pediatric diabetes population is creating demand for child-friendly insulin delivery solutions, including auto-injectors and painless delivery devices.

Another major factor fueling market expansion is the increasing penetration of insulin delivery devices in developing countries. Governments and healthcare organizations are investing in affordable and innovative insulin injection aids to improve diabetes care accessibility. The expansion of telemedicine and digital health solutions is also playing a role in market growth, as patients can now receive real-time guidance on insulin administration through virtual diabetes management platforms.

Furthermore, regulatory support and reimbursement policies are driving the adoption of advanced insulin injection aids. Many healthcare systems now cover smart insulin pens, auto-injectors, and safety syringes, making them more accessible to patients. Additionally, sustainability and eco-friendly design trends are influencing the market, with manufacturers developing biodegradable insulin pen components and recyclable injection aids to reduce medical waste.

As the demand for safer, smarter, and more convenient insulin delivery solutions continues to grow, the insulin injection aids market is set to expand, with innovations in smart technology, personalized dosing, and needle-free insulin delivery shaping the future of diabetes care.

SCOPE OF STUDY:

The report analyzes the Insulin Injection Aids market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Insulin Vial Aids, Syringe Aids, Injectors, Aids for Kids, Others); End-Use (Hospitals, Specialty Clinics, Home Care Settings, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â